Ray Page, DO
Hematology & Oncology · Weatherford, TXNPI 1669422143
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.8%. Reporting peaked in 2023 at $17,237 and has fallen 81.0% since, to $3,275 in 2025.
Across 621 payments — averaging $72.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$5K
- Verastem, Inc.$5K
- Astellas Pharma US Inc$4K
- AbbVie$4K
- Puma Biotechnology, Inc.$3K
- Johnson & Johnson$3K
- plus $20K from 54 others
Across 343 payments — averaging $6969.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$691K
- Incyte Corporation$346K
- Eli Lilly$259K
- Genentech, Inc.$220K
- Exelixis Inc.$174K
- GSK$118K
- plus $583K from 18 others
What the payments were for
- Consulting fees$20,42645%
- Speaking & faculty fees$7,20016%
- Travel & lodging$5911%
- Food & beverage$16,26636%
- Education$5871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Copiktra$5,168
- Venclexta$3,485
- ZEPZELCA$2,413
- ALUNBRIG$1,815
- COSELA$1,500
- LIBTAYO$1,333
- Nerlynx$702
- Avastin$490
- Rituxan$490
- Herceptin$490
- Enhertu$372
- Erleada$300
- Monoferric$272
- Trodelvy$236
- SIR-Spheres Microspheres$147
- OPTUNE LUA (NOVOTTF-200T)$140
- SOMATULINE DEPOT$136
- ONIVYDE$136
- MI CANCER SEEK$131
- KISQALI$125
How this compares
$45,070 in reported general payments places this provider in the 85th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $620,878 |
| ImbruvicaIbrutinib | 40 | $481,508 |
| ErleadaApalutamide | 29 | $432,347 |
| LonsurfTrifluridine/Tipiracil Hcl | 26 | $425,940 |
| JakafiRuxolitinib Phosphate | 22 | $368,771 |
| Lenalidomide | 24 | $359,049 |
| CabometyxCabozantinib S-Malate | 14 | $356,365 |
| VerzenioAbemaciclib | 17 | $254,478 |
| TagrissoOsimertinib Mesylate | 13 | $207,882 |
| Imatinib Mesylate | 34 | $104,292 |
| BrukinsaZanubrutinib | 12 | $84,972 |
| Abiraterone Acetate | 48 | $68,755 |
| EliquisApixaban | 29 | $28,730 |
| Exemestane | 23 | $2,327 |
| Anastrozole | 141 | $1,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $283 | $620,87839 claims |
| Johnson & JohnsonErleada | $3,004 | $432,34729 claims |
| Taiho Oncology, Inc.Lonsurf | $106 | $425,94026 claims |
| Incyte CorporationJakafi | $441 | $368,77122 claims |
| Exelixis Inc.Cabometyx | $289 | $356,36514 claims |
| Lilly USA, LLCVerzenio | $428 | $254,47817 claims |
| AstraZenecaTagrisso | $674 | $207,88213 claims |
| Beigene USA, Inc.Brukinsa | $48 | $84,97212 claims |
| PfizerEliquis | $677 | $28,73029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Weatherford
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.